Form 4 for CAI Caris Life Sciences, Inc.
Accepted 2026-07-13 07:06:08 ET · period of report 2026-05-15 · accession 0001189394-26-000005 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| I | 2026-07-13 07:06 | 2026-05-15 | CAI | HALBERT JON | Dir | P - Purchase | $14.56 | +68.0K | 704.6K | +11% | +$990.1K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-05-15 | P | A | 68,000 | $14.56 | 704,598 | I By LAH Investments, Ltd. | — | — | (F2) The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $14.49 to $14.60 inclusive. The reporting person undertakes to provide to Caris Life Sciences, Inc., any security holder of Caris Life Sciences, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. (F3) Includes an aggregate of 11,598 shares received in pro rata distributions exempt pursuant to Rule 16a-9. (F4) The Reporting Person disclaims beneficial ownership except to the extent of his pecuniary interest therein. |